Evidence map›Paper›PMID 32847973›Full record

ArticleMolecular cancer therapeutics2020

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.

E Gabriela Chiorean, Susan M Perkins, R Matthew Strother, Anne Younger, Jennifer M Funke, Safi G Shahda, Noah M Hahn, Kumar Sandrasegaran, David R Jones, Todd C Skaar and 3 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

E Gabriela ChioreanUniversity of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington. gchiorea@uw.edu.
Susan M PerkinsIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
R Matthew StrotherUniversity of Otago, Christchurch, New Zealand.
Anne YoungerIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Jennifer M FunkeIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Safi G ShahdaIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Noah M HahnJohns Hopkins University, Baltimore, Maryland.
Kumar SandrasegaranMayo Clinic, Rochester, Minnesota.
David R JonesIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Todd C SkaarIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Bryan P SchneiderIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
Christopher J SweeneyDana Farber Cancer Institute, Boston, Massachusetts.
Daniela E MateiNorthwestern University, Chicago, Illinois.ORCID 0000-0003-2169-5035
Indiana University Health · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USJohns Hopkins University · USMayo Clinic · USNorthwestern University · USUniversity of Otago · NZ

Funding

INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
NCRR NIH HHS UL1 RR025761
6 · The paper itself

Abstract

VEGF blockade does not uniformly result in clinical benefit. We evaluated safety, dose-limiting toxicities (DLT), recommended phase II dose (RP2D), antitumor efficacy, and exploratory biomarkers including pharmacogenomics and pharmacokinetics with sorafenib, bevacizumab, and paclitaxel in patients with refractory cancers. The study had a "3 + 3" design, using paclitaxel 80 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabFemaleHumansMaleMiddle AgedNeoplasmsPaclitaxelPharmacogeneticsSorafenibBevacizumabPaclitaxelSorafenib

Identifiers

PMID32847973
PMCPMC7541675
OpenAlexW3081304630

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.